Esperion Announces Positive Phase 2 Clinical Trial Results for ETC-1002Esperion Therapeutics, a privately held biotechnology company in Plymouth, Monday announced positive results from a Phase 2 clinical trial for its potential cholesterol buster, ETC-1002.

More From CBS Detroit

Daily J
Valenti and Foster

Watch & Listen